ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.888+1G>A

dbSNP: rs1135402799
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Human Genetics, Inc, Center for Human Genetics, Inc RCV000659969 SCV000781881 pathogenic Neurofibromatosis, type 1 2016-11-01 criteria provided, single submitter clinical testing
Invitae RCV000659969 SCV000960450 pathogenic Neurofibromatosis, type 1 2023-08-25 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 8 of the NF1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in the gain of 20 amino acid residue(s), but is expected to preserve the integrity of the reading-frame. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with neurofibromatosis type1 (PMID: 10712197, 28961165, 30530636; Invitae). ClinVar contains an entry for this variant (Variation ID: 547573). Studies have shown that disruption of this splice site results in the activation of a cryptic splice site in intron 8 (PMID: 18546366; Invitae). For these reasons, this variant has been classified as Pathogenic.
Genome-Nilou Lab RCV000659969 SCV002561608 pathogenic Neurofibromatosis, type 1 2022-03-15 criteria provided, single submitter clinical testing
Ambry Genetics RCV002442381 SCV002682985 pathogenic Hereditary cancer-predisposing syndrome; Cardiovascular phenotype 2022-03-16 criteria provided, single submitter clinical testing The c.888+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 8 of the NF1 gene. The mutation has been detected in multiple unrelated individuals diagnosed with or suspected of having neurofibromatosis type 1 (NF1) (Fahsold R et al. Am. J. Hum. Genet., 2000 Mar;66:790-818; Ars E et al. J. Med. Genet., 2003 Jun;40:e82; Pros E et al. Hum. Mutat., 2008 Sep;29:E173-93; Frayling IM et al. J. Med. Genet., 2019 04;56:209-219). This mutation was also reported to result in either skipping of exon 8 or activation of a cryptic donor site in intron 8 (Ars E et al. J. Med. Genet., 2003 Jun;40:e82; Pros E et al. Hum. Mutat., 2008 Sep;29:E173-93; Frayling IM et al. J. Med. Genet., 2019 04;56:209-219; Ambry internal data). Furthermore, other variants at the same donor site (c.888+1G>C and c.888+2T>G) have been identified in individuals diagnosed with or suspected of having NF1 (Pasmant E et al. Mol. Med. 2011 Sep;17:79-87; Bonatti F et al. Int J Mol Sci, 2017 Sep;18:). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.